Syncona Limited Autolus publishes Annual Report (4668I)
November 26 2018 - 3:57AM
UK Regulatory
TIDMSYNC
RNS Number : 4668I
Syncona Limited
26 November 2018
Syncona Limited
Autolus publishes Annual Report
26 November 2018
Syncona Ltd, a leading healthcare company focused on investing
in and building global leaders in life science, today notes that
its portfolio company, Autolus Therapeutics plc (NASDAQ: AUTL), a
clinical-stage biopharmaceutical company developing next-generation
programmed T cell therapies, announced that it has filed its annual
report on Form 20-F for the fiscal year ended 2018 with the United
States Securities and Exchange Commission.
The announcement can be found below and the annual report can be
found on Autolus' investor relations website at
https://www.autolus.com/investor-relations/financial-information/sec-filings.
[ENDS]
Enquiries
Syncona Ltd
Annabel Clay
Tel: +44 (0) 20 7611 2010
Tulchan Communications
Martin Robinson
Lisa Jarrett-Kerr
Tel: +44 (0) 207 353 4200
Copies of this press release and other corporate information can
be found on the company website at: www.synconaltd.com
About Syncona
Syncona is a leading FTSE250 healthcare company focused on
investing in and building global leaders in life science. Our
vision is to deliver transformational treatments to patients in
truly innovative areas of healthcare while generating superior
returns for shareholders.
We seek to partner with the best, brightest and most ambitious
minds in science to build globally competitive businesses.
We take a long-term view, underpinned by a deep pool of capital,
and are established leaders in the development of genetic medicine,
particularly gene and cell therapy. We focus on delivering dramatic
efficacy for patients in areas of high unmet need.
About Autolus
Autolus is a biopharmaceutical company developing
next-generation programmed T cell therapies for the treatment of
cancer.
Autolus Therapeutics Submits Fiscal Year 2018 Form 20-F
LONDON, November 23, 2018 -- Autolus Therapeutics plc (NASDAQ:
AUTL), a clinical-stage biopharmaceutical company developing
next-generation programmed T cell therapies, today announced that
it has filed its annual report on Form 20-F for the fiscal year
ended 2018 with the United States Securities and Exchange
Commission. The annual report can be found on Autolus' investor
relations website at
https://www.autolus.com/investor-relations/financial-information/sec-filings.
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing
next-generation, programmed T cell therapies for the treatment of
cancer. Using a broad suite of proprietary and modular T cell
programming technologies, the company is engineering precisely
targeted, controlled and highly active T cell therapies that are
designed to better recognize cancer cells, break down their defense
mechanisms and eliminate these cells. Autolus has a pipeline of
product candidates in development for the treatment of
hematological malignancies and solid tumors. For more information,
go to: https://www.autolus.com
# #
Investor contact:
S.A. Noonan Communications
Susan A. Noonan
+1-212-966-3650
susan@sanoonan.com
International Media Contact:
JW Communications
Julia Wilson
+44 (0)7818 430877
juliawilsonuk@gmail.com
U.S. Media Contact:
Rx Communications Group, LLC
Paula Schwartz
+ 1-917-322-2216
pschwartz@rxir.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
PFUGCBDBBUDBGIL
(END) Dow Jones Newswires
November 26, 2018 04:57 ET (09:57 GMT)
Syncona (LSE:SYNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syncona (LSE:SYNC)
Historical Stock Chart
From Apr 2023 to Apr 2024